237 related articles for article (PubMed ID: 23273076)
1. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
4. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
Sun CH; Chang YH; Pan CC
Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
[TBL] [Abstract][Full Text] [Related]
5. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
[TBL] [Abstract][Full Text] [Related]
6. Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: a tissue microarray study of 149 patients treated by transurethral resection.
Munari E; Chaux A; Maldonado L; Compérat E; Varinot J; Bivalacqua TJ; Hoque MO; Netto GJ
Histopathology; 2015 Jan; 66(2):262-9. PubMed ID: 25039670
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
Bagrodia A; Krabbe LM; Gayed BA; Kapur P; Bernstein I; Xie XJ; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclerq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Margulis V
Urology; 2014 Nov; 84(5):1134-40. PubMed ID: 25443916
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
10. Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate.
Faraj SF; Albadine R; Chaux A; Gonzalez-Roibon N; Hicks J; Humphreys E; Partin A; Netto GJ
Urology; 2013 Nov; 82(5):1083-9. PubMed ID: 24035134
[TBL] [Abstract][Full Text] [Related]
11. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.
Chaux A; Albadine R; Schultz L; Hicks J; Carducci MA; Argani P; Allaf M; Netto GJ
Hum Pathol; 2013 Oct; 44(10):2323-30. PubMed ID: 23953228
[TBL] [Abstract][Full Text] [Related]
13. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
15. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
[TBL] [Abstract][Full Text] [Related]
17. The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.
Wu N; Du Z; Zhu Y; Song Y; Pang L; Chen Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818758772. PubMed ID: 29463194
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
19. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
Shin E; Choi CM; Kim HR; Jang SJ; Park YS
Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]